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Abstract
Deubiquitinating enzymes (DUBs) have been increasingly implicated in regulation of cellular processes, but a functional role
for Ubiquitin C-terminal Hydrolases (UCHs), which has been largely relegated to processing of small ubiquitinated peptides,
remains unexplored. One member of the UCH family, UCH L1, is expressed in a number of malignancies suggesting that this
DUB might be involved in oncogenic processes, and increased expression and activity of UCH L1 have been detected in
EBV-immortalized cell lines. Here we present an analysis of genes regulated by UCH L1 shown by microarray profiles
obtained from cells in which expression of the gene was inhibited by RNAi. Microarray data were verified with subsequent
real-time PCR analysis. We found that inhibition of UCH L1 activates genes that control apoptosis, cell cycle arrest and at the
same time suppresses expression of genes involved in proliferation and migration pathways. These findings are
complemented by biological assays for apoptosis, cell cycle progression and migration that support the data obtained from
microarray analysis, and suggest that the multi-functional molecule UCH L1 plays a role in regulating principal pathways
involved in oncogenesis.
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Introduction
Modification of proteins by ubiquitination is a fundamental
mechanism for regulating numerous cellular processes including
DNA repair, cell cycle regulation, antigen presentation, cell-cell
communication, cell differentiation and apoptosis. Certain alter-
ations in ubiquitination have been shown to lead to uncontrolled
growth, finally leading to tumorigenesis [1]. Deubiquitination is a
reversal of this process, carried out by deubiquitinating enzymes
(DUBs), which are thiol proteases important for regulating
different cellular processes [2]. Ubiquitin C-terminal hydrolase
L1 (UCH L1) belongs to the family of DUBs [3] responsible for
hydrolyzing carboxyl terminal esters and amides of ubiquitin.
Additionally, it also possesses ubiquitin ligase activity [4] and
functions as a mono-ubiquitin stabilizer [5]. This protein was
isolated from the brain and at first considered a neuronal specific-
marker [6]. Mutations in the uch l1 gene are associated with
neurodegenerative disorders such as Parkinson’s, Huntington’s
and Alzheimer’s diseases, but how these mutations relate to these
diseases remains unclear [7].
More recently, UCH L1 has been detected in various types of
malignant tissues [8]. UCH L1 levels are high in acute
lymphoblastic leukemia cells [9], and in non-small cell lung
cancer. UCH L1-positivity is associated with advanced stages of
disease [10]. In addition, UCH L1 has been proposed as a key
regulator of tumor invasion and metastasis [11]. Increased UCH
L1 RNA levels are associated with poor prognosis in invasive
breast cancer, and the protein has been suggested as a prognostic
marker in ER/PR-negative tumors [12]. There is recent evidence
that UCH L1 is highly expressed in pancreatic [13], prostate [14],
medullary thyroid [15], esophageal [16] colorectal carcinomas
[17], and in HPV16-transformed cells [18]. Additionally, UCH
L1-positive renal cancer cells (RCC) had greater rates of
proliferation and migration than UCH L1-negative RCC cells
[19]. Finally, increased UCH L1 expression and activity were
detected in Burkitt’s lymphoma and Epstein-Barr Virus (EBV)-
infected B-lymphocytes [20], and in these cell lines. UCH L1 is
associated with enhanced proliferation and decreased cell
adhesion properties [21].
This evidence suggests that UCH L1 may possess tumorigenic
properties and promote tumor progression, although the mecha-
nism is largely unknown. We wanted to investigate whether UCH
L1 affects known oncogenic processes by utilizing the application
of RNAi and cDNA microarray analyses to gain insight into genes
regulated by UCH L1 in EBV-transformed B-cells and in SV40-
transformed 293T HEK cells.
Our data demonstrate that suppression of UCH L1 causes
alterations in the expression of genes related to cell death,
migration, and cell cycle progression. To confirm the physiolog-
ical consequences of such alterations, we assessed whether UCH
L1 expression affects these pathways in biologic assays. Based on
the results, we suggest that UCH L1 participates in oncogenesis
by promoting proliferation and invasion, and by inhibiting
apoptosis.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6764Results and Discussion
Identification of Genes Differentially Regulated by
Suppression of UCH L1
Microarray analysis to study the effects of UCH L1 on
expression of cellular genes has been done in gad mice, in which
the uch l1 gene is deleted; however gad mice harbor additional
mutations not specific to UCH L1 [22]. In addition, gene-
expression profiles after over-expression of UCH L1 in an
esophageal squamous carcinoma cell line indicated that expression
led to induced expression of plaminogen activator inhibitor (PAI-
1). PAI-1 is associated with cancer growth and metastasis [23]. To
determine the alterations in global gene expression produced by
suppression of UCH L1 levels, we used HEK 293T, SV40-
transformed human embryonic kidney cells that grow as an
adherent culture, and KR4, an EBV-transformed B-cell line that
grows in suspension. These two cell types were chosen in order to
identify a broad spectrum of specific gene-expression changes that
could result from inhibition of UCH L1 expression. For the
analyses, we created stable cell lines expressing GFP and two
different UCH L1 siRNAs (UCH L1 siRNA1 and UCH L1
siRNA2) in both cell types. Total RNA extracted from the GFP
and the two UCH L1 siRNA-expressing cell lines were used in
microarray and QRT-PCR analyses. There was considerable
reduction in UCH L1 RNA and protein levels in the 293T
(Figure 1A) and KR4 cell lines (Figure 1B) expressing UCH L1
but not GFP siRNA. In addition, C33A, an HPV-negative cervical
cancer cell line, was transiently transfected with GFP siRNAs and
two different UCH L1 siRNA to compare the effects of UCH L1
suppression on a primary cancer cell line (Figure 1C). These
Figure 1. Suppression of UCH L1 expression by RNAi. HEK 293T or LCL KR4 cells were transfected with control GFP siRNA or either of two UCH
L1 siRNAs in pRS vector and selected with puromycin. C33A cells were transiently transfected with control GFP siRNA or two UCH L1 siRNAs (for 48 h).
Total RNA was extracted from control and UCH L1 siRNA-expressing cells and quantitative real-time PCR assays performed with gene-specific primers
to determine the UCH L1 RNA levels. Each reaction was performed in triplicate and was normalized to GAPDH as an internal control. Whole-protein
lysates were extracted from control and UCH L1 siRNA-expressing cells, and western blot analysis was performed for UCH L1 or GAPDH protein levels
with specific antibodies. UCH L1 RNA and protein levels are shown for 293T (A) or KR4 (B) and C33A cells (C).
doi:10.1371/journal.pone.0006764.g001
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of effectively reducing UCH L1 RNA and protein levels by
approximately 70% in 293T and KR4 cells. However, in C33A
cells under transient transfection conditions (transfection efficiency
,70–80%), suppression of UCH L1 was approximately 40%. To
avoid off-target effects of siRNA, we employed 2 different siRNAs.
Gene-expression profiles were measured with RNA extracted
from UCH L1 siRNA-expressing cells with the use of Agilent
Whole Human Genome Array (44K) containing ,41,000 unique
probes. To strengthen the experimental design, we used UCH L1
siRNA1 and siRNA2 for KR4 and UCH L1 siRNA1 for 293T
cells, respectively, to determine changes in gene expression. A dye-
swap was performed for both cell types to eliminate dye-bias.
Thus, the total number of RNA samples used for hybridization
with 44K Agilent arrays was 12; altogether 6 arrays were used.
The parameters used to identify significantly altered gene
expression included: fold change of 1.5, Student’s T test,
normalization to the median, quality of 1 and log transformation
of data. In addition, the Benjamini and Hochberg method of
correction was applied to estimate the false discovery rate with a
confidence of 5%. By applying these parameters we identified a
number of statistically significant genes which were analyzed
further for biological consequences of such changes. The quality of
data generated was verified with scatter plots, which provide a
graphical view of alterations in the control versus UCH L1 siRNA
cell lines, for which the log of mean intensity for each pair of
replicates was plotted (Figure 2A).
We next compared the mean values, signal intensities and
distribution across the different samples. Box plots for control and
UCH L1 siRNA samples demonstrate that the mean and range of
signal amplitudes were very similar for all samples (data not
shown). Principal Component Analysis (PCA) abridges the task of
identifying sources of relative variability in a high dimensional data
set by reducing the dimensions, and therefore the complexity, of
the data set. PCA was used to determine the variability among the
data set. As seen in Figure 2B, the UCH L1 siRNA samples
differed from their respective controls and were clustered together
when plotted according to correlation with the first two principal
Figure 2. Identification of Statistically Significant Genes. Scatter-plots of signal intensity comparisons between GFP siRNA and UCH L1 siRNA.
Each point represents a gene and the data: red points represent genes expressed to a higher degree in UCH L1 siRNA along the y-axis and green
points represents genes expressed to a lower degree in UCH L1 siRNA along the x-axis. Grey squares represent genes changed less than 1.5 fold or
with a p-value that failed to reach 0.05 (A). Unsupervised clustering of samples by principal component analysis (B). Each dot represents a gene on
the plot. The distance between any pair of the samples is a function of relative similarity between the two samples. Venn diagram analyses (C) of
gene list common in both cell types. The numbers in the center represent genes that are either up-regulated (left) or down-regulated genes (right) in
common for both 293T and KR4 cells, whereas the numbers within the left circle represent genes regulated in KR4 independently of 293T and vice
versa.
doi:10.1371/journal.pone.0006764.g002
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cell types are different.
Venn diagrams were used to identify the overlapping genes
among different samples. We were interested in determining
common genes regulated by UCH L1 in the two cell types, so we
generated Venn diagrams by combining the separate gene lists
obtained from Genesifter analysis after applying the selected
parameters and then manually identified the common genes in the
two cell types (Figure 2C). Of the total genes affected, 201 unique
genes were up-regulated and 204 were down-regulated, which
were common to both cell types. Table S1 (Table S1) shows the
common gene list assembled from the affected genes. Among
these, some genes were identified more than once as they were
represented on the microarray by more than one probe set, which
provided an additional internal control and increased confidence
in the results. In addition, the Spike-In control showed slopes in
the range of 0.997 to 0.88 across all the arrays, further increasing
confidence in the data set.
Validation of Microarray Data with Quantitative Real
Time-PCR
To validate microarray results, QRT-PCR analysis was
performed for 19 genes encoding proteins with known function.
Genes selected were affected in both cell types and represented
different physiological pathways (proteins involved in cell cycle,
apoptosis, proliferation, and migration) and different ranges of fold
change. We selected a few genes whose expression was altered only
in 293T or in KR4 cells to demonstrate the specificity of the
microarray data. We validated microarray data with respect to
direction of change of expression (up or down) for 293T
(Figure 3A), KR4 (Figure 3B) and for C33A cells (Figure 3C).
We were able to validate some genes detected in only one or either
cell type by microarray. Since the suppression of UCH L1 was
lower in C33A cells, the extent to which these genes were altered
in this cell line was different as compared to the other two cell
lines. A comparison between microarray data and QRT-PCR
showed good correlation (Table 1). The magnitude of changes for
most of the significantly altered genes was larger in QRT-PCR
assays than in the microarray data, as is commonly observed.
Quantitative differences between the QRT-PCR and microarray
results were probably due to variations in efficiency of cDNA
synthesis among samples, primer-dimer formations, mispriming,
and lower efficiency at later cycles as amplification products
compete for DNA polymerase. Also, the normalization method
used for microarray and QRT-PCR assays was different,
especially in the number of genes used for normalization for
microarray versus QRT-PCR.
Inhibition of UCH L1 Expression Induces Cell-Cycle Arrest
and Apoptosis
According to the microarray analyses, inhibition of UCH L1
expression affected genes in multiple pathways, including
transport, transcription, signal transduction, cytoskeleton, cell
cycle, apoptosis, migration, and proliferation. Progression through
cell cycle and inhibition of apoptosis are critical for oncogenesis.
The microarray analysis indicated up-regulation of pro-apoptotic
genes and down-regulation of genes involved in anti-apoptosis and
cell cycle transition as seen in Figure 4A, which was generated
after performing Ingenuity Pathway Analysis (IPA) on the
common list of genes.
To test the role of UCH L1 in these pathways, we performed
functional assays to elucidate the affected pathways. We first
monitored whether UCH L1 suppression affected cell cycle
progression in reduced serum (1%). The UCH L1 siRNA-
expressing cell lines showed an accumulation of cells in the G0/
G1 phase of the cell cycle, with a concomitant decrease in the
proportion of those in S phase in sub-optimal reduced serum
conditions (Figure 4B) for 293T and KR4 cells respectively.
Similar results were obtained with both UCH L1 siRNAs (data not
shown).
Since arrest in G0/G1 phase often leads to induction of
apoptosis, and our data showed up-regulation of pro-apoptotic
and down-regulation of anti-apoptotic genes, we tested whether
UCH L1 siRNA-expressing cell lines were sensitive to induction of
apoptosis. We performed a cell death assay in the presence or
absence of the apoptosis-inducing agent, camptothecin, to
determine cell death-rate by ELISA. The rate of induction of
apoptosis by camptothecin was higher in UCH L1 siRNA-
expressing cell lines as compared with control 293T and KR4 cells
(Figure 4C). There was also an increase in DNA fragmentation in
UCH L1 siRNA-expressing cell lines (Figure S1) treated with
camptothecin, which confirms that the cells were in the last stage
of apoptosis.
The results indicate that loss of UCH L1 expression by siRNA
leads to induction of apoptosis due to arrest in the G0/G1 phase of
cell-cycle. We are confident that the changes were specific to UCH
L1 knockdown and not due to reduced serum levels, because EBV-
transformed LCL are resistant to cell-cycle changes or apoptosis
induction in reduced serum [24]. We did observe minor
differences in cell-cycle profiles when cells were stimulated with
10% serum, but distinct changes in profiles were evident in sub-
optimal reduced serum conditions. It has been reported that LDN-
57444, an inhibitor of UCH L1’s hydrolase activity, induced cell
death via ER stress and also reduced cell viability in neuroblas-
toma cells [25]. Recently, UCH L1 was identified as an anti-
apoptotic molecule when hepatoma cells were induced by UV
radiation, this work supports our findings [26].
G1-S progression is regulated by the controlled expression and
activity of various molecules such as Cyclins D, E and A, CDKs
(CDK4, 6 and 2), CDKIs (INK4 and CIP/KIP family of proteins),
Rb protein, and E2F transcription factors [27]. Our microarray
data demonstrate the down-regulation of Cyclin G1, SerpinB9,
BIRC6, and NAIP with simultaneous up-regulation of p21
WAF1,
CASP10, CARD9, BCCIP, CARD6, BAX, BIK, FASTKD2, and
TNF-family member levels in both cell types.
Interestingly, we observed up-regulation of pRb1 and simulta-
neous down-regulation of the E2F2 gene in 293T cells, whereas in
KR4 there was up-regulation of p53 indicating that probably the
mechanism of action is different in the two cell types. Both
p21
WAF1 and p27
KIP1 are well known tumor suppressors whose
expression is decreased in cancer. The role of p21
WAF1, a CDK
inhibitor, in cell-cycle progression has been well established.
BCCIP increases p21
WAF1 expression and inhibits G1 to S
progression [28]. In addition, we saw up-regulation of p27
KIP1 in
293T cells; p27
KIP1 causes arrest in G1 phase and induces
apoptosis by increasing BAX protein levels [29]. Previous studies
have demonstrated that down-regulation of UCH L1 expression in
lung cancer cells leads to accumulation of p27
KIP1, and an
increased sensitivity to apoptosis. UCH L1 physically interacts
with p27
KIP1, which suggests a role for UCH L1 in p27
KIP1
degradation [30,31]. Our results indicate that loss of UCH L1
expression in both 293T and KR4 cells leads to G0/G1 arrest and
apoptotic cell death. We believe that the mechanism of these
effects is different in each case (Figure 4). These results suggest
that in 293T cells G0/G1 cell-cycle arrest and apoptosis occur as a
result of up-regulation of the Rb1 pathway, whereas in KR4 cells it
occurs as a result of up-regulation of the p53 pathway.
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6764Figure 3. Validation of Selected Microarray Results by QRT-PCR. The same total RNAs isolated from GFP and the 2 UCH L1 siRNA-expressing
cells as used in the microarray experiments were reverse-transcribed and quantitative real-time PCR was performed with gene-specific primers. Each
reaction was performed in triplicate and normalized to their respective GFP siRNA control and also to GAPDH. QRT-PCR analysis for up- and down-
regulated genes for 293T (A) and KR4 (B) and C33A cells (C).
doi:10.1371/journal.pone.0006764.g003
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Migration
Silencing of the uch l1 gene is reported to reduce migration of
H157 lung cancer cells[11]. Our results so far indicated that
knockdown of UCH L1 leads to G0/G1 arrest along with
induction of apoptosis. We next determined if loss of UCH L1
would also affect proliferative and migratory capacities of the cells.
As seen in Figure 5A, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) prolif-
eration assays demonstrate slower growth rates in UCH L1
siRNA-expressing cell lines for both cell types and that the
differences were only apparent on day 3 and day 4 of the assay.
These results might be due to slowly cycling cells in the presence of
UCH L1 siRNA. The delayed effect on proliferation rates might
be because these assays were performed in optimal 10% serum
conditions. We wanted to eliminate changes due to cell cycle arrest
and increased cell death under reduced serum conditions,
therefore the proliferation assays were performed in 10% serum.
We chose the in-vitro scratch assay for 293T adherent cells to
examine their rate of migration by monitoring changes in distance
between the cell boundaries in the scratched monolayers. Control
and 2 different UCH L1 siRNA-expressing 293T cells (2610
4)
were plated in each well of a 6-well plate in 10% serum and were
allowed to grow until confluent before a wound was introduced
into the cell monolayer. The migration of the cells was monitored
for 26 h by Live Cell Imaging (Figure 5B). For lymphoid
suspension cells, migration rate is measured with a transmigration
assay. To examine the transmigration rate of KR4 cells, we plated
10
6 GFP siRNA or UCH L1 siRNA-expressing cells in transwells
with inserts of pore size 3 and 8 mM in a 12-well plate. Medium
containing SDF-1, a B-cell specific factor, was used as a
chemoattractant at a final concentration of 100 ng/ml. The
migrated cells were counted 24 h post-seeding (Figure 5C).
Changes in the rate of growth as well as a decrease in cell motility
and migration of both 293T and KR4 cell lines were apparent
with knockdown of UCH L1 expression. These data suggest that
UCH L1 might be playing a role in cell migration and invasion.
We are confident that the differences in migration rates are due to
more slowly migrating cells, since the proliferation assay did not
show significant differences in growth rate at day 2.
Genes involved in cell proliferation include cyclin D1, E2F, c-
myc, DNA polymerase [32]. E2F family members play a major role
during G1/S transition [33]. C-Myc is an oncogene involved in
various cancers, and over-expression may be related to poor
prognosis. C-Myc drives cell proliferation by up-regulating cyclins
and down-regulating p21. The microarray data showed down-
regulation of E2F, c-myc, and cyclin D1 gene expression and up-
regulation of p21 in UCH L1 siRNA-expressing cells. The cellular
oncogene, c-Myb, up-regulates the mouse UCH L1 promoter
[34]. The microarray data showed down-regulation of Myb in
UCH L1 siRNA-expressing cells 293T cells. This finding provided
clues for further analysis of UCH L1 promoter sequence for the
presence of putative binding sites for other factors. Interestingly,
the UCH L1 promoter revealed c-Myc and E2F binding sites
indicating that UCH L1 might be playing a role in proliferation
via these molecules. The UCH L1 promoter also possessed
binding sites for Twist2 and SMAD3, which were down-regulated,
and LFA1, EGR1 and HNF4G, which were up-regulated in the
microarray data in one of the two cell types. In addition, the UCH
L1 promoter possesses binding sites for Lef1/TCF4 and the data
demonstrate down-regulation of Lef1 in the 293T and TCF4 in
the KR4 cell lines. Our data also demonstrate a positive feedback
loop between regulation of UCH L1 and b-catenin indicating that
UCH L1 affects this major oncogenic pathway [35] . These data
encourage speculation that there may be correlation between
Table 1. Comparison of Microarray and QRT-PCR Data.
Down-regulated genes 293T Cells * 293T Cells # KR4 LCL * KR4 LCLs #
LEF1 21.82 0.51 Not detected No change
TWIST 28.2 0.24 Not detected No change
FN1 22.74 0.14 Not detected No change
RHOA 21.62 0.47 Not detected 0.58
JAK1 2.1 64 0.33 21.67 0.35
ISG15 21.6 0.12 22.1 0.6
MYC 21.85 0.36 Not detected 0.28
PXN 24.85 0.36 2 2.31 0.53
TCF4 Not detected No change 21.52 0.65
MUC3A 22.88 0.25 23.35 0.28
BIRC6 Not detected 0.78 21.75 0.84
MKI67 Not detected No change 21.57 0.29
Up-regulated genes 293T Cells * 293T Cells # KR4 LCL * KR4 LCLs #
BAX 1.73 4.25 2.09 1.63
BIK 1.71 2.2 1.59 2.41
APC 1.58 1.79 Not detected No change
CDKN1A 2.57 5.11 1.58 1.29
SIAH2 1.52 1.37 1.71 1.34
FASTKD2 1.67 1.45 1.57 1.34
*Microarray fold change, # Quantitative real time PCR fold change
doi:10.1371/journal.pone.0006764.t001
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6764Figure 4. UCH L1 Suppression Induces G0/G1 Arrest and Apoptosis. Ingenuity pathway analysis was performed on genes in common between
UCH L1 siRNA-expressing 293T and KR4 cell lines, after which tox list was generated for genes affecting apoptosis and cell-cycle (A). Cell-cycle analysis
was performed on UCH L1 siRNA-expressing 293T (left panel) and KR4 (right panel) cells (B) after culturing the cells under sub-optimal reduced serum
(1%) conditions for 24 h. For the analysis, 10
6 cells were collected, fixed and stained with propidium iodide and then analyzed with flow cytometry.
Representative histograms are shown in which cell count vs DNA content was plotted. Cell-cycle statistics were generated with ModFit software. To
measure apoptosis, 293T andKR4 cells (10
4) were treated with 3 and6 mM concentrations of camptothecin for 10 h in (1%) serum. Thenumberof viable
cells was measured with a Cell Death ELISA assay, which measures the production of histone-associated DNA fragments at 405 nm wavelength. Each
reaction was performed in duplicate. Graphical representation of cell death rate in 293T (left panel) and KR4 (right panel) cells (C).
doi:10.1371/journal.pone.0006764.g004
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PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6764Figure 5. UCH L1 Suppression Inhibits Cell Proliferation and Migration. For cell proliferation assays, exact numbers of GFP or UCH L1 siRNA-
expressing cells were cultured and cell proliferation rate was measured over a period of 4 days at absorbance at 490 nm for 293T (left panel) or KR
(right panel) cells (A). Each reaction was performed in triplicate and data were calculated as a percentage of GFP siRNA. The proliferation rate of GFP
siRNA cells was taken as 100%. Cell migration was assayed by wound healing for 293T cells and transmigration assay for KR4 cells. Cells were seeded
on 6-well plates and grown to confluence in 10% serum. A scratch was introduced by scraping with a 10-ml pipette tip across the center of the
monolayer. The cells were allowed to migrate and were monitored with Live Cell Imaging for 26 h. Images were collected every 30 m at 8 different
locations for each control and UCH L1 siRNA-expressing 293T cell lines (B). Migration rate was calculated by measuring the distance between 2 points
on the scratch for 6 different time points. For transwell migration, the same number of cells was seeded in the transwell (3 and 8-mM pore-size inserts)
and the number of cells that migrated to the lower chamber were counted after 24 h (C). The data are expressed (wound assay and transmigration)
as a percentage of GFP siRNA results, which was considered to be 100%.
doi:10.1371/journal.pone.0006764.g005
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specific gene products on the UCH L1 promoter.
The most lethal property of a malignant cell is its ability to
metastasize. Adherent cells are bound to each another and to an
extracellular matrix via cell adhesion molecules. In cancer cells, these
molecules are either ablated or are compromised. Cell adhesion is
essential for cell growth, migration and differentiation.The molecules
that play roles in cell adhesion include cadherins, integrins, collagen,
laminins, and cytoskeletal proteins. Important molecules involved in
migration and invasion include fibronectin, paxillin, Rho, TIMPs,
MMPs and many more [36]. The microarray data for 293T cells
showed up-regulation of cadherins, integrins, actin, and myosin and
at the same time down-regulation of vimentin, fibronectin and
paxillin. Up-regulation of fibronectin and paxillin has been associated
with malignant properties of cells [37,38].
Recently, UCH L1 was shown to enhance the invasive capacity,
cell adhesion and morphology of a lung cancer cell line via the
AKT pathway, where phosphorylated AKT is reduced in the
absence of UCH L1, although total AKT levels are not affected
[11]. The phosphorylated form of AKT is the active form involved
in tumorigenesis. The microarray data showed up-regulation of
the akt gene in UCH L1 siRNA-expressing 293T cells, although
we saw down-regulation of the phosphorylated AKT protein in
these cells (Figure S2). These data indicate that UCH L1 might
be mediating its effects on migration via the AKT pathway. Our
microarray data also correlate with recently published data on the
role of UCH L1 in B-cell proliferation and invasion [21]. Up-
regulation of LFA-1 and its ligand ICAM was observed in UCH
L1 siRNA-expressing KR4 cells. We also saw down-regulation of
RhoA in UCH L1 siRNA-expressing 293T cells with the
microarray and with QRT-PCR assays in KR4 cells. RhoA
expression is increased in cancer and is required for migration and
invasion of lymphoid tumor cells [39]. These data provide
evidence that UCH L1 is involved in cell migration and invasion.
For further insight into genes regulated by UCH L1, we
performed pathway analysis using the Ingenuity Pathway Analysis
(IPA) [40], (www.ingenuity.com). Based on available data, this
software created a highly ranked network (pathway model) from the
list of genes we provided (Figure 6A). This network includes 29
genes whose products function in controlling cell death, cellular
growth and proliferation and cell cycle. This information from IPA
provides additional support forourresults fromphysiological assays.
Taken together, the results of this study support the hypothesis
that UCH L1 promotes tumor progression by inhibiting apoptosis
and increasing cell proliferation and migration (Figure 6B).
Exactly how UCH L1 regulates expression of these target genes
will need further investigation. Besides being a deubiquitinating
enzyme, UCH L1 has other activities [7] which are likely to play
roles in other effects of this multi-functional protein.
Materials and Methods
Cell Culture
The human embryonic kidney 293T (HEK 293T) and C33A
(HPV negative cervical cancer) cell lines ware cultured in DMEM
(Sigma) supplemented with 10% FBS (Sigma) and penicillin–
streptomycin. The lymphoblastoid cell line KR4 [41] was cultured
in RPMI 1640 medium plus 10% heat-inactivated FBS and 100
units/ml penicillin–streptomycin. All cell lines were maintained at
37uCi n5 %C O 2 in air.
Establishment of Stable UCH L1 siRNA Cells
UCH L1 siRNA and GFP siRNA was purchased from OriGene
Technologies, Inc, in the form of an shRNA expression plasmid.
The siRNAs used in the experiments are as follows: UCH L1
siRNA1: 59 TGTGGCACAATCGGACTTATTCACGCAGT
39; UCH L1 siRNA2: 59 CCATGATGCCGTGGCACAG-
GAAGGCCAAT 39. Stable cell lines were established as described
in Supporting Information S1.
Transient Transfections of UCH L1 siRNA
C33A cells were transiently transfected with UCH L1 siRNA1
and UCH L1 siRNA2 using Fugene HD (Roche) and RNA as well
as protein were extracted 48 h post transfections.
RNA Isolation, Probe Labeling and DNA Microarray
All experiments were performed according to the manufactur-
er’s instructions. Total RNA was extracted with the use of Total
RNA isolation mini kit (Agilent). The quality of RNA preparations
was assessed on the Agilent 2100 Bioanalyzer with RNA 6000
Nano Reagents and RNA samples of RNA Integrity Number
(RIN) 9.5 or above were used for all microarray experiments.
One microgram of total RNA (control and test) samples was
amplified and labeled to generate cDNA for oligo microarrays
with the Agilent low RNA input linear amplification kit (Cat. No
5184–3523). RNA Spike-Ins were used as internal control. The
dye incorporation rate (between 1.4 and 1.6 pmol/ml) was
measured with a NanodropH ND-1000 spectrophotometer
(Agilent). Hybridization was performed using the Gene expression
hybridization kit (Cat. No. 5188–5242) as described in Supporting
Information S1.
Statistical Data Analysis
The normalized data obtained from the Agilent Feature
extraction software were pre-processed and all the internal control
data points were eliminated. The data files were then analyzed
with GeneSifter microarray data analysis software (VizX Labs).
The parameters used to identify statistically significantly regulated
genes were: Global normalization: median, Quality: 1, log
transformation, threshold of 1.5-fold and Student’s t-test with
correction factor for false discovery rate (Benjamini and Hoch-
berg). This software enables identification of differentially
expressed genes and establishes biological significance based on
Gene Ontology (GO) classification into biological process,
molecular function and cellular component based on a z-score
report. A z-score can be used to identify ontologies or pathway
terms that are significantly over or under-expressed in a gene-list.
Reverse Transcription and Real Time PCR (QRT PCR)
Assay
Reverse transcription was performed with 500 ng total RNA
(same as used in microarray experiments) using the iScript cDNA
synthesis kit (Bio-Rad). A 1:25 dilution of the cDNA reaction
mixture was used in the QRT PCR reaction. QRT-PCR was
carried out in a 15 ml reaction mixture with gene-specific primers
with the iQ-SYBR green kit (Bio-Rad). PCR conditions: 95uC-3
min, and 45 cycles of 95uC for 15 sec, 55uC for 45 sec on the ABI
HT 7600 PCR instrument. All samples were assayed in triplicate.
The differences in expression of gene-specific primers were
evaluated using a relative quantification method in which the
expression of specific gene was normalized to the reference gene
GAPDH. The primers used are shown in (Table S2).
Immunoblot
Total cell lysates or immunocomplexes were resolved on 12% SDS-
PAGE, transferred to PVDF membrane (GE Healthcare), blocked in
5% milk-Tris-buffered saline solution, and incubated at 4uCo v e r n i g h t
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AKT (Cell Signaling, 1:1000) and GAPDH (1:5000, Sigma) antibodies
followed with horse-radish peroxidase-conjugated secondary antibody.
Proteins were detected with the Super Signal West Pico Chemilumi-
nescence Detection Kit (Pierce Biotechnology, Rockford, IL, USA) and
exposed to Kodak XAR-5 film.
Figure 6. Ingenuity pathway analysis (IPA) network representation of the highly scored network. The genes that are shaded red are up-
regulated and those that are green are down-regulated. The intensity of the color shows the degree of up-or down-regulation. A solid line represents
a direct interaction while a dotted line represents an indirect interaction between the two gene products (A). Working Model: Increased expression
of UCH L1 in malignant cells leads to cell cycle progression, increased proliferation and migration and at the same time abrogation of apoptotic
pathways and immune responses and thus promotes tumor progression (B).
doi:10.1371/journal.pone.0006764.g006
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1610
5KR4 GFP or either of two UCH L1 siRNA cells were seeded
in BD Biocoat 3-mma n d8 - mmp o r es i z ec o n t r o lc e l lc u l t u r ei n s e r t s( B D
Biosciences) in RPMI-complete medium (10% FBS). The bottom
chamber contained medium and 100 ng/ml SDF-1achemoattractant.
After an overnight incubation, cells that had migrated to the lower
chamber of the transwell were collected and counted using a
hemocytometer. The experiment was performed in duplicate.
Proliferation MTS Assay
5,000 HEK 293T or 25,000 LCL KR4 cells were seeded in
each well of 96-well plates for each GFP siRNA or two UCH L1
siRNA cells in a volume of 200 ml. CellTiter 96H Aqueous One
Solution Cell Proliferation Assay (Promega) was used to determine
the rate of proliferation following the manufacturer’s instructions.
MTS reagent 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium was added from day 1 to
4 for 4 h and absorbance measured at 490 nm with a 550 plate-
reader (Bio-Rad). The absorbance for each sample was subtracted
from the blank and plotted.
Live Cell Scratch Assay
HEK 293T stable UCH L1 or GFP siRNA-expressing cells were
grown until they formed a monolayer in a 6-well plate in DMEM
complete selection media. A wound was introduced in the
monolayer of cells by scratching with a p10 pipette tip. Cells were
washed twice with PBS to remove debris and given fresh media.
The scratch was assigned time 0. Cells were allowed to proliferate
and migrate into the wound during the next 26 h and images were
collected for each cell type every 40 m, and migration of cells into
the wound was recorded under a phase contrast view with Olympus
IX70 inverted fluorescence microscope with a 4x phase objective.
Apoptosis Assay by ELISA
Induction of apoptosis was measured by using the Cell Death
ELISA Plus kit (Roche) to detect apoptotic nucleosomes. 10
4 GFP or
UCH L1 siRNA cells (HEK 293T or LCL KR4) were seeded in 96-
well plates and each was treated either with DMSO or 3 or 6 mm
concentrations of Camptothecin. After 16 h, histone-associated DNA
fragments were quantified at 405 nm following the manufacturer’s
instructions. Each reaction was performed in duplicate.
FACS Profile for Cell Cycle Analysis
For cell cycle analysis, cells were synchronized were seeded at
60% confluency and cultured for 24 h in reduced serum (1%).
HEK 293T cells were trypsinized and harvested, washed once
with cold phosphate-buffered saline, gently fixed with 80% cold
ethanol, and incubated at 4uC for overnight. Fixed cells were
centrifuged and resuspended in DNA-staining solution (1 mg/ml
RNase A, 0.5 mg/ml propidium iodide), incubated at 37uC for 30
m and subjected to flow cytometry. DNA content was measured
using Cytomation Summit software (Dako). Cell cycle was
analyzed by ModFit LT software (Verity Software).
Supporting Information
Supporting Information S1 Detailed materials and methods
Found at: doi:10.1371/journal.pone.0006764.s001 (0.03 MB
DOC)
Figure S1 Analysis of apoptotic DNA ladder. UCH L1 siRNA-
expressing showed DNA-ladder formation after being cultured in
reduced serum (1%) and 3 uM camptothecin for 10 h.
Found at: doi:10.1371/journal.pone.0006764.s002 (1.32 MB TIF)
Figure S2 Western blot analysis showing role of AKT pathway.
Western blot analysis was performed for pAKT, Total AKT, or
GAPDH protein levels with specific antibodies on whole cell
lysates extracted from 293T control and UCH L1 siRNA-
expressing cells.
Found at: doi:10.1371/journal.pone.0006764.s003 (0.80 MB TIF)
Table S1 List of genes regulated by UCH L1 commonly in
293T and KR4 cell lines
Found at: doi:10.1371/journal.pone.0006764.s004 (0.59 MB
DOC)
Table S2 List of QRT-PCR primers
Found at: doi:10.1371/journal.pone.0006764.s005 (0.05 MB
DOC)
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